Semaglutide vs Liraglutide
Semaglutide and liraglutide are both GLP-1 receptor agonists used in metabolic optimization. Semaglutide is weekly and demonstrates greater average weight loss; liraglutide is daily and is largely legacy in contemporary practice.
Semaglutide is the modern default GLP-1 in metabolic optimization due to weekly dosing and superior weight-loss outcomes.
Liraglutide is appropriate only in select legacy or insurance-driven contexts and is not currently in the oMeds formulary.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is daily dosing ever preferred?
Rarely — weekly dosing improves adherence and outcomes for most candidates.
How is candidacy determined?
Through a synchronous provider-reviewed assessment evaluating metabolic biomarkers, BMI, and contraindications.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment